Compare
Sarepta Therapeutics, Inc. vs Royalty Pharma plc vs United Therapeutics Corp vs Alkermes plc.
| Latest fiscal year | Sarepta Therapeutics, Inc. SRPT | Royalty Pharma plc RPRX | United Therapeutics Corp UTHR | Alkermes plc. ALKS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.20B | $2.38B | $3.18B | $1.48B |
| Revenue growth (YoY) | +15.6% | +5.1% | +10.6% | -5.2% |
| Gross margin | n/a | n/a | 87.9% (computed) | 86.7% (computed) |
| Operating margin | -31.8% | 65.6% | 46.9% | 17.2% |
| Net margin | -32.5% | 32.4% | 41.9% | 16.4% |
| Net income | -$713.41M | $770.95M | $1.33B | $241.66M |
| EPS (Diluted) | -$7.13 | $1.78 | $27.86 | $1.43 |
| Operating cash flow | -$205.48M | $2.49B | $1.56B | $520.75M |
| Free cash flow | -$307.45M | n/a | $1.04B | $480.33M |
| Cash & equivalents | $801.28M | $618.70M | $1.56B | $388.57M |
| Total assets | $3.35B | $19.62B | $7.88B | $2.49B |
| Total liabilities | $2.21B | $9.91B | $783.80M | $667.70M |
| Shareholders' equity | $1.14B | $9.71B | $7.10B | $1.82B |
| Return on year-end equity | -62.5% | 7.9% | 18.8% | 13.3% |
| Shares outstanding | 104.96M | n/a | 43.64M | 165.61M |
Revenue, most recent five fiscal years
| Fiscal year | Sarepta Therapeutics, Inc. | Royalty Pharma plc | United Therapeutics Corp | Alkermes plc. |
|---|---|---|---|---|
| Latest | $2.20B Ended 2025-12-31 | $2.38B Ended 2025-12-31 | $3.18B Ended 2025-12-31 | $1.48B Ended 2025-12-31 |
| 1 year earlier | $1.90B Ended 2024-12-31 | $2.26B Ended 2024-12-31 | $2.88B Ended 2024-12-31 | $1.56B Ended 2024-12-31 |
| 2 years earlier | $1.24B Ended 2023-12-31 | $2.35B Ended 2023-12-31 | $2.33B Ended 2023-12-31 | $1.66B Ended 2023-12-31 |
| 3 years earlier | $933.01M Ended 2022-12-31 | $2.24B Ended 2022-12-31 | $1.94B Ended 2022-12-31 | $1.11B Ended 2022-12-31 |
| 4 years earlier | $701.89M Ended 2021-12-31 | $2.29B Ended 2021-12-31 | $1.69B Ended 2021-12-31 | $1.17B Ended 2021-12-31 |